Anticoagulation strategies for patients undergoing percutaneous coronary intervention: Unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors

Spyros Kokolis; Erdal Cavusoglu; Luther T. Clark; Jonathan D. Marmur

doi:10.1016/j.pcad.2004.02.002

Anticoagulation strategies for patients undergoing percutaneous coronary intervention: Unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors

Spyros Kokolis, Erdal Cavusoglu, Luther T. Clark, Jonathan D. Marmur

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Low-molecular-weight heparins and direct thrombin inhibitors are emerging as alternative anticoagulants to unfractionated heparin in patients undergoing percutaneous coronary intervention (PCI). This paper reviews the pharmacologic properties of these newer antithrombotic agents and evaluates the clinical data demonstrating their use in patients undergoing PCI.

Original language	English
Pages (from-to)	506-523
Number of pages	18
Journal	Progress in Cardiovascular Diseases
Volume	46
Issue number	6
DOIs	https://doi.org/10.1016/j.pcad.2004.02.002
State	Published - 2004
Externally published	Yes

Access to Document

10.1016/j.pcad.2004.02.002

Cite this

@article{e9097edac51241bbab01c60acffe6214,

title = "Anticoagulation strategies for patients undergoing percutaneous coronary intervention: Unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors",

abstract = "Low-molecular-weight heparins and direct thrombin inhibitors are emerging as alternative anticoagulants to unfractionated heparin in patients undergoing percutaneous coronary intervention (PCI). This paper reviews the pharmacologic properties of these newer antithrombotic agents and evaluates the clinical data demonstrating their use in patients undergoing PCI.",

author = "Spyros Kokolis and Erdal Cavusoglu and Clark, {Luther T.} and Marmur, {Jonathan D.}",

year = "2004",

doi = "10.1016/j.pcad.2004.02.002",

language = "English",

volume = "46",

pages = "506--523",

journal = "Progress in Cardiovascular Diseases",

issn = "0033-0620",

publisher = "W.B. Saunders",

number = "6",

}

Anticoagulation strategies for patients undergoing percutaneous coronary intervention: Unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors. / Kokolis, Spyros; Cavusoglu, Erdal; Clark, Luther T. et al.
In: Progress in Cardiovascular Diseases, Vol. 46, No. 6, 2004, p. 506-523.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Anticoagulation strategies for patients undergoing percutaneous coronary intervention

T2 - Unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors

AU - Kokolis, Spyros

AU - Cavusoglu, Erdal

AU - Clark, Luther T.

AU - Marmur, Jonathan D.

PY - 2004

Y1 - 2004

N2 - Low-molecular-weight heparins and direct thrombin inhibitors are emerging as alternative anticoagulants to unfractionated heparin in patients undergoing percutaneous coronary intervention (PCI). This paper reviews the pharmacologic properties of these newer antithrombotic agents and evaluates the clinical data demonstrating their use in patients undergoing PCI.

AB - Low-molecular-weight heparins and direct thrombin inhibitors are emerging as alternative anticoagulants to unfractionated heparin in patients undergoing percutaneous coronary intervention (PCI). This paper reviews the pharmacologic properties of these newer antithrombotic agents and evaluates the clinical data demonstrating their use in patients undergoing PCI.

UR - http://www.scopus.com/inward/record.url?scp=2942750024&partnerID=8YFLogxK

U2 - 10.1016/j.pcad.2004.02.002

DO - 10.1016/j.pcad.2004.02.002

M3 - Article

C2 - 15224257

AN - SCOPUS:2942750024

SN - 0033-0620

VL - 46

SP - 506

EP - 523

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

IS - 6

ER -

Anticoagulation strategies for patients undergoing percutaneous coronary intervention: Unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors

Abstract

Access to Document

Fingerprint

Cite this